Literature DB >> 16979888

Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study).

Marc Colonna1, Enrico Grande, Jón G Jónasson.   

Abstract

We described the relative survival of thyroid cancer cases diagnosed in Europe during the period 1990-1994 and analysed time trends in relative survival during the period 1983-1994 using the EUROCARE-3 database. Relative survival of thyroid cancers is one of the highest amongst cancer sites, with age-standardised relative survival rates of 74% in men and 82% in women over the period 1990-1994, with marked differences between countries. The higher relative survival rates are observed in Scandinavian countries and the lower rates are observed in the UK and the countries of Eastern Europe. Relative survival is higher in women than in men, and decreases with age whatever the histological group. There are significant differences in relative survival according to histological type. Relative survival has slightly increased over the period 1983-1994 only when all histological types have been considered together. Time trend was, however, non-existent when the different histological groups were taken into account except during the most recent period of observation. One possible explanation for the differences in relative survival between countries and sex may probably be found in the changes in thyroid classification and diagnosis techniques. When these changes are not homogeneous, the distribution of thyroid cancers by histology and by stage at diagnosis may be very different. The only way to understand these differences is to conduct specific studies including a description of stage at diagnosis, diagnosis procedures used for staging and details of treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16979888     DOI: 10.1016/j.ejca.2006.04.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Classical and follicular variant papillary thyroid carcinoma: comparison of clinical, ultrasonographical, cytological, and histopathological features in 444 patients.

Authors:  Didem Ozdemir; Reyhan Ersoy; Neslihan Cuhaci; Dilek Arpaci; Eren P Ersoy; Birol Korukluoglu; Gulnur Guler; Bekir Cakir
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

2.  GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Authors:  Jean-Philippe Spano; Y Vano; S Vignot; T De La Motte Rouge; L Hassani; R Mouawad; F Menegaux; D Khayat; L Leenhardt
Journal:  Med Oncol       Date:  2011-09-25       Impact factor: 3.064

3.  Scoring System for Mortality in Patients Diagnosed with and Treated Surgically for Differentiated Thyroid Carcinoma with a 20-Year Follow-Up.

Authors:  David López-Bru; Antonio Palazón-Bru; David Manuel Folgado-de la Rosa; Vicente Francisco Gil-Guillén
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

4.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  Scott N Pinchot; Rebecca S Sippel; Herbert Chen
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.